The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • No CSPEC related information was provided by the message!

  • See Evidence submitted by expert panel for details.

Variant: NM_000540.2(RYR1):c.6671G>A (p.Arg2224His)

CA308104313

478260 (ClinVar)

Gene: RYR1
Condition: malignant hyperthermia, susceptibility to, 1
Inheritance Mode: Autosomal dominant inheritance
UUID: 406f38a4-31d0-4501-8dec-e52efdd70496
Approved on: 2023-04-07
Published on: 2023-04-07

HGVS expressions

NM_000540.2:c.6671G>A
NM_000540.2(RYR1):c.6671G>A (p.Arg2224His)
NC_000019.10:g.38496416G>A
CM000681.2:g.38496416G>A
NC_000019.9:g.38987056G>A
CM000681.1:g.38987056G>A
NC_000019.8:g.43678896G>A
NG_008866.1:g.67717G>A
ENST00000599547.6:n.6671G>A
ENST00000359596.8:c.6671G>A
ENST00000355481.8:c.6671G>A
ENST00000359596.7:n.6671G>A
ENST00000360985.7:c.6668G>A
ENST00000594335.5:n.123G>A
NM_001042723.1:c.6671G>A
NM_000540.3:c.6671G>A
NM_001042723.2:c.6671G>A
NM_000540.3(RYR1):c.6671G>A (p.Arg2224His)
More

Uncertain Significance

Met criteria codes 1
PM1
Not Met criteria codes 5
PS4 PP3 BA1 BS1 BP4

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Malignant Hyperthermia Susceptibility VCEP
This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of Arginine with Histidine at codon 2224 of the RYR1 protein, p.(Arg2224His). The maximum allele frequency for this variant among the six major gnomAD populations is SAS: 0.000033, a frequency consistent with pathogenicity for MHS. This variant has been reported as a variant of uncertain significance (PMID:30155738) and has an entry in ClinVar. No functional studies were identified for this variant. This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). A REVEL score of 0.605 supports neither a pathogenic nor a benign status for this variant. This variant has been classified as a Variant of Unknown Significance. Criteria implemented: PM1.
Met criteria codes
PM1
This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704).
Not Met criteria codes
PS4
This variant has been reported as a variant of uncertain significance (PMID:30155738) and has an entry in ClinVar.
PP3
A REVEL score of 0.605 supports neither a pathogenic nor a benign status for this variant.
BA1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4
A REVEL score of 0.605 supports neither a pathogenic nor a benign status for this variant.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.